Taking advantage of the overexpression and roles of GPR56 in NSCLC, designing a vaccine containing BL and HTL epitopes to induce immune responses against GPR56-overexpressing NSCLC is a potent strategy. The gene discussed is ADGRG1; the disease is non-small cell lung carcinoma.